Intranasal delivery of recombinant human parathyroid hormone [hPTH (1-34)], teriparatide in rats

Endocrine Research

Volumn 30, Issue 3, 2004, Pages 455-467

  Agu, Remigius U ^a   Valiveti, Satyanarayana ^a   Earles, D Caroline ^a   Klausner, Mitchell ^b   Hayden, Patrick J ^b   Wermeling, Daniel P ^a,c   Stinchcomb, Audra L ^a  

^a University of Kentucky   (United States)

^b MATTEK CORPORATION   (United States)

^c Intranasal Technology Incorporated   (United States)

Author keywords

Human parathyroid hormone; Nasal absorption; Nasal tissue; Nasal toxicity; Pharmacokinetics; Teriparatide

Indexed keywords

BOVINE SERUM ALBUMIN; CELL MARKER; PARATHYROID HORMONE[1-34]; RECOMBINANT HORMONE;

ANIMAL EXPERIMENT; AQUEOUS SOLUTION; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG SCREENING; ELECTRIC RESISTANCE; IN VIVO STUDY; MALE; NONHUMAN; NOSE MUCOSA; POTENTIAL DIFFERENCE; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RAT;

ADMINISTRATION, INTRANASAL; ANIMALS; BODY FLUID COMPARTMENTS; DRUG DELIVERY SYSTEMS; INJECTIONS, SUBCUTANEOUS; MALE; NASAL MUCOSA; PARATHYROID HORMONE; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; TERIPARATIDE; TISSUE CULTURE TECHNIQUES;

EID: 7544236962     PISSN: 07435800     EISSN: None     Source Type: Journal    
DOI: 10.1081/ERC-200035957     Document Type: Article

References (25)

1. Nemeth EF. Pharmacological regulation of parathyroid hormone secretion. Curr Pharm Des 2002; 8(23):2077-2087.
2. Ashworth LE. Teriparatide [hPTH-(1-34)] - a recombinant human parathyroid hormone fragment with anabolic actions for the treatment of osteoporosis. Formulary 2002; 37(3):129-133.
3. Campion JM, Maricic MJ. Osteoporosis in men. Am Fam Phys 2003; 67(7): 1521-1526.
4. Body JJ, Gaich GA, Scheele WH, Kulkarni PM, Miller PD, Peretz A, Dore RK, Correa-Rotter R, Papaioannou A, Cumming DC, Hodsman AB. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 2002; 87(10):4528-4535.
5. Body JJ. Management of primary osteoporosis. Acta Clin Belg 2002; 57(5):277-283.
6. Abramowicz M. Teriparatide (Forteo) for osteoporosis. Med Lett 2003; 45(1149): 9-12.
7. Leone-Bay A, Sato M, Paton D, Hunt AH, Sarubbi D, Carozza M, Chou J, McDonough J, Baughman RA. Oral delivery of biologically active parathyroid hormone. Pharm Res 2001; 18(7):964-970.
8. Codrons V, Vanderbist F, Verbeeck RK, Arras M, Lison D, Preat V, Vanbever R. Systemic delivery of parathyroid hormone (1-34) using inhalation dry powders in rats. J Pharm Sci 2003; 92(5):938-950.
9. Patton JS, Trinchero P, Platz RM. Bioavailability of pulmonary delivered peptides and proteins-alpha-interferon, calcitonins and parathyroid hormones. J Control Release 1994; 28(1-3):79-85.
10. Wolff RK, Allen DL, Hughes BL, Smith HW, Chou JZ, Bowsher RR, Francis PC, Vahle JL. The case for route-dependent toxicology comparisons: using large animal models to speed clinical development of inhaled proteins. Respir Drug Deliv 2000; 7:163-170.
11. Suzuki Y, Nagase Y, Iga K, Kawase M, Oka M, Yanai S, Matsumoto Y, Nakagawa S, Fukuda T, Adachi H, Higo N, Ogawa Y. Prevention of bone loss in ovariectomized rats by pulsatile transdermal iontophoretic administration of human PTH (1-34). J Pharm Sci 2002; 91(2):350-361.
12. Chang SL, Hofmann GA, Zhang L, Deftos LJ, Banga AK. The effect of electroporation on iontophoretic transdermal delivery of calcium regulating hormones. J Control Release 2000; 66(2-3):127-133.
13. Kohno T, Murasugi N, Sakurai H, Watabe K, Nakamuta H, Koida M, Sugie Y, Nomura M, Yanagawa A. Development of a highly sensitive and specific two-site enzyme immunoassay for parathyroid hormone (1-34): application to pharmacokinetic study on intranasal parathyroid hormone (1-4) in human. J Clin Lab Anal 1998; 12(5):268-275.
14. Fox J. Developments in parathyroid hormone and related peptides as bone-formation agents. Curr Opin. Pharmacol 2002; 2(3):338-344.
15. Patton JS. Pulmonary delivery of drugs for bone disorders. Adv Drug Deliv Rev 2000; 42(3):239-248.
16. Hayden PJ, Klausner M, Kubilus J, Jackson R, Roemer EJ. Reproducibility of Epiairway®, a differentiated airway tissue model for pre-clinical drug development studies. Abstracts of Papers American Thoracic Society (ATS) International Conference, Seattle, WA, May 19, 2003.
17. El-Shafyl MA, Roemer E, deMeireles J, Biswas M, Quay SC. Permeability and cytotoxicity of macromolecule from nasal formulation using EpiAirway® tissue model. AAPSPharmSci 2001; 3(3):Supplemental Abstract M2389.
18. Illium L. Nasal delivery: the use of animal models to predict performance in man. J Drug Target 1996; 3(6):427-442.
19. Quay S, Quay SC, deMeireles J, Wormuth D, Vangalla S, Biswas M. Effects of enhancers on macromolecules formulations on membrane penetration, cell viability and resistance using EpiAirway® tissue model. AAPSPharmSci 2001; 3(3):Supplemental Abstract M2388.
20. Hussain AA, Dakkuri A, Itoh S. Nasal absorption of ondansetron in rats: an alternative route of drug delivery. Cancer Chemother Pharmacol 2000; 45(5):432-434.
21. Mundy GR, Guise TA. Hormonal control of calcium homeostasis. Clin Chem 1999; 48(B):1347-1352.
22. Morley P, Whitfield JF, Willick GE, Ross V, MacLean S, Isaacs RJ, Mendoza E, Barbier JR. Prolonged low-dose infusion of human parathyroid hormone does not increase femoral cancellous bone volume in ovariectomized rats. Eur J Endocrinol 1999; 141:70-74.
23. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997; 138(11):4607-4612.
24. Arnaud SB, Goldsmith RS, Stickler GB, McCall JT, Arnaud CD. Serum parathyroid hormone and blood minerals: interrelationships in normal children. Pediat Res 1973; 7:485-493.
25. Scotto-Lavino E, Easow J, Simon S, Roemer E. An in vitro model for the rapid screening of potential components and formulations for nasal drug delivery. In Vitro Cell Dev Biol 2002; 38:12.